People · Operator
Named in public records as an officer, director or promoter · active 2009–2020 · Other Health Care, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| DermTech, Inc. | — | Other Health Care | Series C | $98.9M | $1.5B | 2020 |
| Novelix Pharmaceuticals Inc | — | Pharmaceuticals | Pre-Seed | $253K | $12.0M | 2009 |
Burkhard Jansen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Burkhard Jansen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Gary Jacobs | 1 | 11 |
| Enrico Picozza | 1 | 7 |
| Gene Salkind | 1 | 5 |
| Michael Willis | 1 | 4 |
| Matthew Posard | 1 | 4 |
| Cynthia Collins | 1 | 2 |
| Kevin Sun | 1 | 2 |
| Timothy Triche | 1 | 2 |
| Gene Salkind, M.D. | 1 | 1 |
| Zuxu Yao | 1 | 1 |
| Herm Rosenman | 1 | 1 |
| Todd Wood | 1 | 1 |
| Carl Peck, M.D. | 1 | 1 |
| Jeremy Teraoka | 1 | 1 |
| John Dobak, M.D. | 1 | 1 |
| Scott Pancoast | 1 | 1 |
| Steven Kemper | 1 | 1 |
| John Dobak | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.